Pharmaceutical

MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

Mar 27, 2025 - 06:00
MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor
MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.
Read the original article

Tags:

Previous Article

Character Biosciences gains $93m for precision eye disease therapies

Next Article

Immunovant will not pursue approval for the autoimmune medication

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: More biotechs are betting on obesity; Pfizer RSV vaccine faces hurdles in low-income countries

STAT+: Pharmalittle: More biotechs are betting on obesi...

May 1, 2023

STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news

STAT+: Pharmalittle: We’re reading about Lilly selling ...

Jan 6, 2024

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

May 15, 2024